Metformin for Treatment of Psoriasis Combined With Disorders of Glucose and Lipid Metabolism
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Psoriasis and metabolic disorders are well-known mutual comorbidities. The investigators
hypothesized metformin can ameliorate both psoriasis and metabolic disorders mainly via gut
microbiota modulation. The investigators design a randomized, double-blind,
placebo-controlled study to evaluate the efficacy and safety of treatment of metformin for
psoriasis combined with disorders of glucose and lipid metabolism and to explore the role of
gut microbiota during the process.